Annual Report and AGM Notice

RNS Number : 5309L

Alliance Pharma PLC

19 April 2018

 

For immediate release

19 April 2018

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company") 

Annual Report and AGM Notice

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, confirms that it has today published the following documents on its website, investors.alliancepharmaceuticals.com/, in compliance with AIM rule 26:

·     the Annual Report for the year ended 31 December 2017

·     an explanatory circular containing the notice of the Annual General Meeting, to be held on 24 May 2018

·     a proxy form for shareholders to vote at the AGM

Hard copies of all three documents have been posted to all shareholders.

This announcement is released in compliance with AIM rule 20.

For further information:

Alliance Pharma plc                                                                                          + 44 (0) 1249 466966

John Dawson, Chief Executive Officer

Peter Butterfield, Deputy Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

Buchanan                                                                                                        + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Gemma Mostyn-Owen

Numis Securities Limited                                                                                 + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black / Toby Adcock

Investec Bank plc                                                                                             + 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Rob Baker

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

MSCZMGMDVLZGRZM